Marco Peradotto

Dr. Marco Peradotto

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
ABAlessandro Bondi
Alessandro Bondi
ACAntonio Curtoni
Antonio Curtoni
MPMarco Peradotto
Marco Peradotto
EZElisa Zanotto
Elisa Zanotto
Matteo BoattiniMatteo Boattini
Matteo Boattini
CCCristina Costa
Cristina Costa
Background: Fosfomycin is an old bactericidal drug that has gained increasing interest in the last decade for its potential use in multi-drug resistant gram-negative infections. However, evidence on fosfomycin susceptibility testing reports a poor correlation between commercial methods vs. reference agar dilution (AD) for Enterobacterales (EB). The study aimed at assessing the performance of two automated systems for the determination of fosfomycin susceptibility in EB clinical isolates. Methods: Fosfomycin susceptibility testing results of two collections of 100 non-duplicate clinical EB strains obtained using two different platforms (BD Phoenix and MicroScan WalkAway Plus) were compared with those obtained by AD. Categorical agreement (CA), major error (ME) and very major error (VME) rates were calculated. Results: BD Phoenix exhibited a 6.9% rate of false-resistant results and achieved a CA of 69%, whereas MicroScan WalkAway Plus achieved 3.7% of false-resistant results and 72% of CA. Both automated systems showed poor detection of resistant isolates, with 49.1% and 56.2% of false-susceptible results for BD Phoenix and Microscan WalkAway Plus, respectively. Conclusions: Overall, agar dilution remains the most suitable method for routine laboratory antimicrobial susceptibility testing of fosfomycin on Enterobacterales strains, given the poor performance of automated systems. The application of both automated systems, in the clinical laboratories reporting of fosfomycin, should be reviewed in light of the accuracy results falling below the acceptable threshold.

16 February 2022 in Infection
Verified
Journal Article
Closed access
PDF file
MPMarco Peradotto
Marco Peradotto
ABA. Bondi
A. Bondi
DLD. Lombardi
D. Lombardi
PBP. Bottino
P. Bottino
EZE. Zanotto
E. Zanotto
RCR. Cavallo
R. Cavallo

6 August 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
ABAlessandro Bondi
Alessandro Bondi
EKEmanuele Koumantakis
Emanuele Koumantakis
ACAntonio Curtoni
Antonio Curtoni
ABAnna Maria Barbui
Anna Maria Barbui
MPMarco Peradotto
Marco Peradotto
CCCristina Costa
Cristina Costa
Background: The international surveillance of antimicrobial resistance (AMR) reports S. pneumoniae as one of leading causes of death associated with AMR. Against invasive disease, several vaccinations are available and a reduction in AMR in S. pneumoniae has been observed. Here, we evaluated the impact of anti-pneumococcal vaccination policy and the SARS-CoV2 outbreak on AMR in S. pneumoniae causing invasive disease. Methods: We collected all strains of S. pneumoniae causing invasive disease from 2008 in the Piedmont region (Italy). Each strain was typed in order to identify the serogroup and data about AMR were collected. The population under surveillance was classified as infants, children, adults, and the old population. Results: We collected n = 2076 S. pneumoniae strains, with 21.9% and 40.3% being resistant to penicillin G and erythromycin, respectively. We reported an increased risk of infection with penicillin-resistant S. pneumoniae among all populations and evaluated whether the infection was caused by a serotype included in the vaccine formulation. A similar increase was observed after the SARS-CoV2 outbreak. Conclusions: In the Piedmont region, subsequently to the introduction of anti-pneumococcal vaccination, a significant increase in the risk of penicillin G-resistant invasive pneumococcal disease among infants and old population was reported. No significant impact was found for the SARS-CoV2 outbreak.

1 February 2021 in Parasitology International
Verified
Journal Article
Closed access
MPMarco Peradotto
Marco Peradotto
EREmanuela Rolle
Emanuela Rolle
TZTeresa Zaccaria
Teresa Zaccaria
Serena CavalleroSerena Cavallero
Serena Cavallero
ABAlessandro Bondi
Alessandro Bondi
RCRossana Cavallo
Rossana Cavallo

15 September 2022 in Microbial Drug Resistance
Verified
Journal Article
Closed access
MPMarco Peradotto
Marco Peradotto
ABAlessandro Bondi
Alessandro Bondi
GBGabriele Bianco
Gabriele Bianco
MIMarco Iannaccone
Marco Iannaccone
ABAnna Maria Barbui
Anna Maria Barbui
RCRossana Cavallo
Rossana Cavallo
The lack of internationally approved breakpoint and a handy susceptibility testing reduces fosfomycin usefulness against Pseudomonas aeruginosa . Previous works defined low or moderate agreement between commercial methods and the reference method (agar dilution [AD]). In particular, data lack about testing against P. aeruginosa . We compared disk diffusion (DD), E-test (ET), and automated broth microdilution (BMD) to AD by testing 150 P. aeruginosa isolates. We obtained better categorical agreement (CA) for DD and ET for minimal inhibitory concentration >128 mg/L (84.7% and 92.7%, respectively), but with high very major error (VME). BMD had the lowest VME rate (2/42), but with 64% CA and 52/108 major errors. We cannot define a method comparable to AD. Larger studies, as well as the definition of a breakpoint value are needed for fosfomycin against P. aeruginosa.

1 April 2021 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
ABAlessandro Bondi
Alessandro Bondi
MPMarco Peradotto
Marco Peradotto
GBGabriele Bianco
Gabriele Bianco
DGDavide Ghibaudo
Davide Ghibaudo
ABAnna Maria Barbui
Anna Maria Barbui
RCRossana Cavallo
Rossana Cavallo